Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Novartis has agreed to invest in, and possibly buy, Gamida Cell, an Israeli company developing stem cell therapies. Novartis will pay $35 million for a 15% stake in Gamida and an option to buy the company if it meets certain clinical milestones by the first half of 2016. If Novartis exercises the option, it will pay another $165 million and up to $435 million in milestone payments. Gamida has a treatment for hematological malignancies, such as leukemia and lymphoma, in early-stage clinical trials.
This article has been sent to the following recipient: